Jeil Pharmaceutical to Participate in BIO-Europe 2026, Pursue Overseas Business Expansion
Pursuing Out-Licensing of JP-2266 and JP9441
Jeil Pharmaceutical will pursue out-licensing and co-development of key drug candidates while strengthening global partnerships to expand overseas markets for its internally developed medicines.
Jeil Pharmaceutical announced on November 9 that it will participate in BIO-Europe 2026, which will be held in Cologne, Germany, from November 9 to 11 (local time).
At the event, Jeil Pharmaceutical plans to strengthen its network with global pharmaceutical companies and pursue partnering activities focused on out-licensing and co-development of key drug candidates, as well as overseas licensing of its medicines. The company aims to expand the foundation for global collaboration and identify overseas business opportunities.
At the event, Jeil Pharmaceutical plans to present its type 2 diabetes drug candidate JP-2266, its anticancer drug candidate JP9441, and its combination therapy for diabetes, Duglow, as key partnering assets, and explore opportunities for out-licensing and overseas business cooperation with global pharmaceutical companies.
JP-2266 is a type 2 diabetes treatment that works through a dual-inhibition mechanism, simultaneously inhibiting SGLT2, which is involved in glucose reabsorption in the kidneys, and SGLT1, which is involved in glucose absorption in the small intestine. The company is preparing to advance the candidate into Phase 3 clinical trials.
JP9441 is an anticancer drug candidate based on a SOS1 inhibitor that regulates the activation of the KRAS protein, which is involved in cancer cell proliferation. It is being developed to treat solid tumors, including KRAS-mutant lung, colorectal, and pancreatic cancers.
Jeil Pharmaceutical is also seeking to expand overseas markets for Duglow, a combination therapy for type 2 diabetes that has been launched in South Korea. Duglow combines dapagliflozin and pioglitazone, bringing two active ingredients with different mechanisms of action together in a single tablet.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kim Sumi, head of Jeil Pharmaceutical's Global Business Division, said, "At BIO-Europe, we plan to showcase the competitiveness of our key drug candidates and products and expand opportunities for collaboration with global pharmaceutical companies. Through ongoing partnering activities, we will identify out-licensing and overseas business opportunities and broaden our business foundation in global markets."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
